Format
Sort by
Items per page

Send to

Choose Destination

UI-R-C1-ln-c-01-0-UI.s1 UI-R-C1 Rattus norvegicus cDNA clone UI-R-C1-ln-c-01-0-UI 3', mRNA sequence [Rattus norvegicus]

Search results

Items: 1 to 20 of 125

1.

Research priorities to inform "Treat All" policy implementation for people living with HIV in sub-Saharan Africa: a consensus statement from the International epidemiology Databases to Evaluate AIDS (IeDEA).

Yotebieng M, Brazier E, Addison D, Kimmel AD, Cornell M, Keiser O, Parcesepe AM, Onovo A, Lancaster KE, Castelnuovo B, Murnane PM, Cohen CR, Vreeman RC, Davies MA, Duda SN, Yiannoutsos CT, Bono RS, Agler R, Bernard C, Syvertsen JL, Sinayobye JD, Wikramanayake R, Sohn AH, von Groote PM, Wandeler G, Leroy V, Williams CF, Wools-Kaloustian K, Nash D; IeDEA Treat All in sub-Saharan Africa Consensus Statement Working Group.

J Int AIDS Soc. 2019 Jan;22(1):e25218. doi: 10.1002/jia2.25218. Review.

2.

Global temporal changes in the proportion of children with advanced disease at the start of combination antiretroviral therapy in an era of changing criteria for treatment initiation.

Panayidou K, Davies MA, Anderegg N, Egger M; IeDEA, COHERE, PHACS and IMPAACT 219C Collaborations Writing Group.

J Int AIDS Soc. 2018 Nov;21(11):e25200. doi: 10.1002/jia2.25200.

3.

Mortality and losses to follow-up among adolescents living with HIV in the IeDEA global cohort collaboration.

Kariminia A, Law M, Davies MA, Vinikoor M, Wools-Kaloustian K, Leroy V, Edmonds A, McGowan C, Vreeman R, Fairlie L, Ayaya S, Yotebieng M, Takassi E, Pinto J, Adedimeji A, Malateste K, Machado DM, Penazzato M, Hazra R, Sohn AH; IeDEA.

J Int AIDS Soc. 2018 Dec;21(12):e25215. doi: 10.1002/jia2.25215.

4.

Adolescent pregnancy at antiretroviral therapy (ART) initiation: a critical barrier to retention on ART.

Nuwagaba-Biribonwoha H, Kiragga AN, Yiannoutsos CT, Musick BS, Wools-Kaloustian KK, Ayaya S, Wolf H, Lugina E, Ssali J, Abrams EJ, Elul B; International epidemiology Databases to Evaluate AIDS (IeDEA) East Africa Collaboration.

J Int AIDS Soc. 2018 Sep;21(9):e25178. doi: 10.1002/jia2.25178.

5.

Trends Over Time for Adolescents Enrolling in HIV Care in Kenya, Tanzania, and Uganda From 2001-2014.

Apondi E, Humphrey JM, Sang E, Mwangi A, Keter A, Musick BS, Nalugoda FK, Ssali J, Bukusi E, Yiannoutsos CT, Wools-Kaloustian K, Ayaya S.

J Acquir Immune Defic Syndr. 2018 Oct 1;79(2):164-172. doi: 10.1097/QAI.0000000000001796.

PMID:
29985263
6.

Models of support for disclosure of HIV status to HIV-infected children and adolescents in resource-limited settings.

Arrivé E, Ayaya S, Davies MA, Chimbetete C, Edmonds A, Lelo P, Fong SM, Razali KA, Kouakou K, Duda SN, Leroy V, Vreeman RC; IeDEA Pediatric Working Group.

J Int AIDS Soc. 2018 Jul;21(7):e25157. doi: 10.1002/jia2.25157.

7.

Optimal timing of HIV home-based counselling and testing rounds in Western Kenya.

Olney JJ, Eaton JW, Braitstein P, Hogan JW, Hallett TB.

J Int AIDS Soc. 2018 Jun;21(6):e25142. doi: 10.1002/jia2.25142.

8.

Access to antiretroviral therapy in HIV-infected children aged 0-19 years in the International Epidemiology Databases to Evaluate AIDS (IeDEA) Global Cohort Consortium, 2004-2015: A prospective cohort study.

Desmonde S, Tanser F, Vreeman R, Takassi E, Edmonds A, Lumbiganon P, Pinto J, Malateste K, McGowan C, Kariminia A, Yotebieng M, Dicko F, Yiannoutsos C, Mubiana-Mbewe M, Wools-Kaloustian K, Davies MA, Leroy V; International Epidemiology Databases to Evaluate AIDS (IeDEA) Pediatric Working Group.

PLoS Med. 2018 May 4;15(5):e1002565. doi: 10.1371/journal.pmed.1002565. eCollection 2018 May.

9.

Impact of Antiretroviral Regimens on Cerebrospinal Fluid Viral Escape in a Prospective Multicohort Study of Antiretroviral Therapy-Experienced Human Immunodeficiency Virus-1-Infected Adults in the United States.

Mukerji SS, Misra V, Lorenz DR, Uno H, Morgello S, Franklin D, Ellis RJ, Letendre S, Gabuzda D.

Clin Infect Dis. 2018 Sep 28;67(8):1182-1190. doi: 10.1093/cid/ciy267.

10.

HIV treatment eligibility expansion and timely antiretroviral treatment initiation following enrollment in HIV care: A metaregression analysis of programmatic data from 22 countries.

Tymejczyk O, Brazier E, Yiannoutsos C, Wools-Kaloustian K, Althoff K, Crabtree-RamĂ­rez B, Van Nguyen K, Zaniewski E, Dabis F, Sinayobye JD, Anderegg N, Ford N, Wikramanayake R, Nash D; IeDEA Collaboration.

PLoS Med. 2018 Mar 23;15(3):e1002534. doi: 10.1371/journal.pmed.1002534. eCollection 2018 Mar.

11.

Late Presentation With HIV in Africa: Phenotypes, Risk, and Risk Stratification in the REALITY Trial.

Siika A, McCabe L, Bwakura-Dangarembizi M, Kityo C, Mallewa J, Berkley J, Maitland K, Griffiths A, Baleeta K, Mudzingwa S, Abach J, Nathoo K, Thomason MJ, Prendergast AJ, Walker AS, Gibb DM; REALITY Trial Team .

Clin Infect Dis. 2018 Mar 4;66(suppl_2):S140-S146. doi: 10.1093/cid/cix1142.

12.

Time to First-Line ART Failure and Time to Second-Line ART Switch in the IeDEA Pediatric Cohort.

Wools-Kaloustian K, Marete I, Ayaya S, Sohn AH, Van Nguyen L, Li S, Leroy V, Musick BS, Newman JE, Edmonds A, Davies MA, Eboua FT, Obama MT, Yotebieng M, Sawry S, Mofenson LM, Yiannoutsos CT.

J Acquir Immune Defic Syndr. 2018 Jun 1;78(2):221-230. doi: 10.1097/QAI.0000000000001667.

PMID:
29509590
13.

The epidemiology of adolescents living with perinatally acquired HIV: A cross-region global cohort analysis.

Collaborative Initiative for Paediatric HIV Education and Research (CIPHER) Global Cohort Collaboration, Slogrove AL, Schomaker M, Davies MA, Williams P, Balkan S, Ben-Farhat J, Calles N, Chokephaibulkit K, Duff C, Eboua TF, Kekitiinwa-Rukyalekere A, Maxwell N, Pinto J, Seage G 3rd, Teasdale CA, Wanless S, Warszawski J, Wools-Kaloustian K, Yotebieng M, Timmerman V, Collins IJ, Goodall R, Smith C, Patel K, Paul M, Gibb D, Vreeman R, Abrams EJ, Hazra R, Van Dyke R, Bekker LG, Mofenson L, Vicari M, Essajee S, Penazzato M, Anabwani G, Q Mohapi E, N Kazembe P, Hlatshwayo M, Lumumba M, Goetghebuer T, Thorne C, Galli L, van Rossum A, Giaquinto C, Marczynska M, Marques L, Prata F, Ene L, Okhonskaia L, Rojo P, Fortuny C, Naver L, Rudin C, Le Coeur S, Volokha A, Rouzier V, Succi R, Sohn A, Kariminia A, Edmonds A, Lelo P, Ayaya S, Ongwen P, Jefferys LF, Phiri S, Mubiana-Mbewe M, Sawry S, Renner L, Sylla M, Abzug MJ, Levin M, Oleske J, Chernoff M, Traite S, Purswani M, Chadwick EG, Judd A, Leroy V.

PLoS Med. 2018 Mar 1;15(3):e1002514. doi: 10.1371/journal.pmed.1002514. eCollection 2018 Mar.

14.

Retention and mortality on antiretroviral therapy in sub-Saharan Africa: collaborative analyses of HIV treatment programmes.

Haas AD, Zaniewski E, Anderegg N, Ford N, Fox MP, Vinikoor M, Dabis F, Nash D, Sinayobye JD, Niyongabo T, Tanon A, Poda A, Adedimeji AA, Edmonds A, Davies MA, Egger M; African regions of the International epidemiologic Databases to Evaluate AIDS (IeDEA).

J Int AIDS Soc. 2018 Feb;21(2). doi: 10.1002/jia2.25084.

15.

Adherence to antiretroviral therapy in a clinical cohort of HIV-infected children in East Africa.

Vreeman RC, Ayaya SO, Musick BS, Yiannoutsos CT, Cohen CR, Nash D, Wabwire D, Wools-Kaloustian K, Wiehe SE.

PLoS One. 2018 Feb 21;13(2):e0191848. doi: 10.1371/journal.pone.0191848. eCollection 2018.

16.

Global Trends in CD4 Cell Count at the Start of Antiretroviral Therapy: Collaborative Study of Treatment Programs.

IeDEA and COHERE Cohort Collaborations .

Clin Infect Dis. 2018 Mar 5;66(6):893-903. doi: 10.1093/cid/cix915.

17.

Increased prevalence of pregnancy and comparative risk of program attrition among individuals starting HIV treatment in East Africa.

Holmes CB, Yiannoutsos CT, Elul B, Bukusi E, Ssali J, Kambugu A, Musick BS, Cohen C, Williams C, Diero L, Padian N, Wools-Kaloustian KK.

PLoS One. 2018 Jan 17;13(1):e0190828. doi: 10.1371/journal.pone.0190828. eCollection 2018.

18.

Trends in hepatitis B virus testing practices and management in HIV clinics across sub-Saharan Africa.

Coffie PA, Egger M, Vinikoor MJ, Zannou M, Diero L, Patassi A, Kuniholm MH, Seydi M, Bado G, Ocama P, Andersson MI, Messou E, Minga A, Easterbrook P, Anastos K, Dabis F, Wandeler G; IeDEA collaboration.

BMC Infect Dis. 2017 Nov 1;17(Suppl 1):706. doi: 10.1186/s12879-017-2768-z. Review.

19.

Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up results from a randomised controlled trial.

Hakim JG, Thompson J, Kityo C, Hoppe A, Kambugu A, van Oosterhout JJ, Lugemwa A, Siika A, Mwebaze R, Mweemba A, Abongomera G, Thomason MJ, Easterbrook P, Mugyenyi P, Walker AS, Paton NI; Europe Africa Research Network for Evaluation of Second-line Therapy (EARNEST) Trial Team.

Lancet Infect Dis. 2018 Jan;18(1):47-57. doi: 10.1016/S1473-3099(17)30630-8. Epub 2017 Nov 3.

20.

Modeling the causal effect of treatment initiation time on survival: Application to HIV/TB co-infection.

Hu L, Hogan JW, Mwangi AW, Siika A.

Biometrics. 2018 Jun;74(2):703-713. doi: 10.1111/biom.12780. Epub 2017 Sep 28.

Supplemental Content

Loading ...
Support Center